Amgen (AMGN) Accumulated Expenses (2009 - 2026)

Amgen's Accumulated Expenses history runs 18 years deep, the most recent figure standing at $16.6 billion for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 3.78% year-over-year to $16.6 billion; the TTM figure through Mar 2026 stood at $16.6 billion (down 3.78% YoY), while the FY2025 annual figure was $18.5 billion, up 5.0% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $16.6 billion, down from $18.5 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $18.5 billion in Q4 2025, with the low at $10.5 billion in Q2 2022.
• The 5-year median for Accumulated Expenses is $14.2 billion (2023), against an average of $14.4 billion.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses jumped 30.09% in 2023, then slipped 3.78% in 2026.
• Amgen's Accumulated Expenses stood at $12.5 billion in 2022, then climbed by 22.64% to $15.4 billion in 2023, then rose by 14.86% to $17.6 billion in 2024, then rose by 5.0% to $18.5 billion in 2025, then fell by 10.47% to $16.6 billion in 2026.
• Business Quant data shows AMGN's Accumulated Expenses at $16.6 billion in Q1 2026, $18.5 billion in Q4 2025, and $16.8 billion in Q3 2025.